Context: Craniopharyngioma (CP), Rathke's cyst (RC), and xanthogranuloma (XG) are closely related rare sellar masses. Treatment strategies in children lack consensus.
C raniopharyngiomas (CPs) are cystic epithelial tumors of the sellar region of low histological grade. CPs account for 1.2-4.6% of all intracranial tumors, corresponding to 0.5-2.5 new cases per million population per year (1) (2) . Several observations indicate that CPs arise from neoplastic transformation of ectodermal cell remnants of Rathke's pouch and the craniopharyngeal duct (3) . It has been proposed that CPs and Rathke's cysts (RCs) may represent a continuum of ectodermally derived epithelial lesions (4, 5) . XG of the sellar region is histologically composed of cholesterol clefts, macrophages (xanthoma cells), chronic inflammatory cellular reaction, and hemosiderin deposits. Xanthogranuloma (XG) of the sellar region represents a clinicopathological entity distinct from adamantinomatous CP (4) . Accordingly, CP, RC, and sellar XG are closely related lesions. Prospective studies comparing clinical manifestations and the impact of various therapeutic strategies on prognoses do not yet exist for patients with childhoodonset CP, XG, or RC. Therefore, the dispute between advocates supporting a radical surgical treatment vs. those favoring a biopsy followed by irradiation is not yet settled. In HIT-Endo (6) and KRANIOPHARYNGEOM 2000 (7) , clinical manifestations, recurrence/progression rates, and sequelae of patients with childhood-onset CP, XG, and RC were evaluated prospectively.
Patients and Methods

Patients
Patients with an original diagnosis of childhood CP (n ϭ 117; 57 female, 60 male), XG (n ϭ 14; six female, eight male) were recruited from 2001-2006 by 54 participating centers for the prospective trial KRANIOPHARYNGEOM 2000 (NCT00258453) (7) . Patients with RC (n ϭ 14; six female, eight male) had been recruited by HIT-Endo (1996 (6) and KRANIOPHARYNGEOM 2000 KRANIOPHARYNGEOM (2001 KRANIOPHARYNGEOM -2006 . Both studies were approved by the local standing committee on ethical practice, and informed consent was obtained from patients and/or their parents, depending on the patients' legal age to grant consent.
Neuroradiological imaging
Cranial magnetic resonance imaging (MRI) was performed prospectively, according to recommendations set by KRANIO-PHARYNGEOM 2000 (8, 9) , at diagnosis and at 3-month intervals during follow-up (Fig. 1 ). The assessment of localization, volume, progression/recurrence, hypothalamic involvement, and the degree of surgical resection was based on pre-and postsurgical MRI and prospectively confirmed by central, blinded, neuroradiological reference review in all cases. Volume of the sellar/parasellar mass was estimated based on the maximal diameters of the mass in three dimensions on MRI [volume (cubic centimeters) ϭ a ϫ b ϫ c/2], and progression was defined as a more than 25% increase in volume. The degree of hypothalamic involvement/surgical lesion was evaluated as published (7): grade 0 (zero degree), no hypothalamic involvement/lesion; grade 1 (first degree), hypothalamic involvement/ lesion of the anterior hypothalamus not involving the mammillary bodies and the hypothalamic area beyond mammillary bodies; and grade 2 (second degree), hypothalamic involvement/lesion of the anterior and posterior hypothalamic area, i.e. involving the mammillary bodies and the area beyond mammillary bodies. Calcifications were assessed by computed tomography.
Neurosurgery
Neurosurgical interventions were performed in 50 centers. Based on their neurosurgery patient load during the 6-yr recruitment period, centers were categorized as small (one patient/6 yr), middle-sized (two to five patients/6 yr), or large (more than five patients/6 yr) centers.
Evaluation of obesity
Body height and weight SD score (SDS) (10) were prospectively obtained before and at 3-month intervals after diagnosis. Body mass index (BMI) (weight in kilograms divided by height in meters squared) was calculated as SDS (11) for each subject at diagnosis and at last follow-up evaluation.
Histological analysis
Histological diagnoses were confirmed by central, blinded, neuropathological reference review in all cases. All available histological sections were reviewed, determin-ing histological characteristics of all sellar masses using routine light microscopic evaluation of paraffin sections stained with hematoxylin and eosin stain (Fig. 2) . Each specimen was evaluated for the presence or the absence of features of adamantinomatous CP corresponding to ameloblastoma or calcifying odontogenic cyst, other types of epithelium, tubular structures, adenohypophyseal tissue, cholesterol crystals, collections of foamy cells, foreign-body giant cells, lymphoplasmacellular infiltrates, hemosiderin, necrosis, fibrotic tissue, and calcification. In addition, immunohistochemistry was performed for cytokeratins (antibody Lu-5; Bachem, Weil am Rhein, Germany) and Ki-67 (antibody MIB-1; Dako, Hamburg, Germany) in all cases where paraffin material was available.
Clinical parameters, therapy, and follow-up
Based on KRANIOPHARYNGEOM 2000 (12) and HITEndo (6), clinical features of all patients were collected. Endocrine status was assessed with regard to hormonal substitution of deficient hypothalamic-pituitary axes.
The duration of history was assessed based on patients' records. The occurrence of clinical manifestations before diagnosis and the frequency of these symptoms as an initial manifestation were quantified.
Irradiation was performed in 39 of 117 CP patients (33%) as conformable-dose fractionated percutaneous radiation therapy, with conventional fractionated target volume doses of 50.0 -55.8 Gy (mean 50.4 Gy). Four CP patients (3%) were treated with stereotactic ␥-knife radiotherapy (total single dose was 10 -16 Gy, mean 13.5 Gy). Two of the 14 RC patients (14%) were treated by conformable-dose fractionated percutaneous radiation therapy (mean dose was 52.2 Gy; range 50.4 -54.0 Gy). Irradiation was not performed in XG patients.
Quality of life (QoL)
The Pediatric Quality of Life Questionnaire (PEDQOL) defining health-related QoL within seven domains (self-esteem, emotion, body image, cognition, physical abilities, social function family, and social function friends) was used to evaluate the patients' self-assessed QoL (7). Functional capacity was assessed using the MunsterHeidelberg Abilities Scale (FMH), which quantifies the ability to perform everyday psychomotor tasks by age-specific percentiles for functional capability (13) . 
Statistical methods
Results
Pretreatment manifestations
Gender distribution and age at diagnosis were similar among all patients. After a follow-up of 5.4 yr (2.7-10.1 yr) in XG, 7.2 yr (0.7-28.2 yr) in RC, and 6.2 yr (0.1-10.7 yr) in CP, patients were evaluated (Table 1) .
Patients with CP presented with the highest (P Ͻ 0.001) volume of sellar/parasellar masses (median 10.3 cm 3 ; range 1.6 -128.7 cm 3 ) compared with XG patients (3.9 cm 3 ; range 0.6 -8.4 cm 3 ) and RC patients (3.4 cm 3 ; range 2.3-6.5 cm 3 ). Calcifications were found more frequently (P Ͻ 0.05) in CP (73%) when compared with XG (38%) and RC (0%). Tumor localization extended more frequently (P Ͻ 0.01) to the suprasellar area in CP (97%) and XG (92%) patients in comparison with RC (29%), as did the frequency (P Ͻ 0.01) of hypothalamic involvement of the sellar mass in CP (82%) and XG (46%) patients compared with 0% hypothalamic involvement in RC patients. Hypothalamic involvement of XG was confined to anterior hypothalamic structures (first degree, 46%), whereas in CP, anterior and posterior hypothalamic structures were involved in 22% (first degree) and 59% (second degree), respectively. Hydrocephalus was detectable in 38% of CP and 15% of RC patients, whereas no XG patient presented with radiological signs of increased intracranial pressure (P ϭ 0.004).
The duration of symptom history as noted in the patients' records was longer in XG (18 months; range 1-96 months) and RC (24 months; 1-84 months) when compared with CP (5 months; 0.3-84 months). Headache was the most frequently recorded initial symptom in CP patients (46%; interval to diagnosis, 5 months; range, 0.25-72 months) and XG patients (63%; interval to diagnosis, 15 months, range, 1-96 months), as compared with RC (23%; interval to diagnosis, 2 months, range, 1-24 months). Weight gain as initial symptom was found in very few records of CP patients (6%), with a median interval to diagnosis of 18 months (range, 6 -60 months). Growth retardation was the most frequent first symptom in the history of RC patients (57%) when compared with XG (21%) and CP (17%). The occurrence of growth retardation was correlated with diagnosis (P ϭ 0.004) (Fig. 3) .
Visual impairment at the time of diagnosis was frequent in CP (55%) compared with XG (15%) and RC (7%) patients. This pattern of differing severity among the three diseases was similar in degree of obesity (BMI SDS) at the time of diagnosis (P ϭ 0.03) and at last evaluation (P Ͻ 0.001). CP patients presented with higher BMI SDS at the time of diagnosis (median BMI, ϩ1.0 SD; range, Ϫ5.0 to ϩ9.9) and at last follow-up (median BMI, ϩ2.9 SDS, range, Ϫ1.8 to ϩ14.6) compared with XG (BMI at diagnosis, Ϫ0.6 SDS; range, Ϫ2.1 to ϩ1.7, P ϭ 0.018; and BMI at last evaluation, 0.1 SDS; range, Ϫ2.3 to ϩ4.1, P Ͻ 0.001, respectively) and RC patients (BMI at diagnosis, Ϫ0.5 SDS, range, Ϫ1.5 to ϩ5.3, P ϭ 0.19; and BMI at last evaluation, Ϫ0.1 SDS; range, Ϫ1.4 to ϩ5.9, P Ͻ 0.001, respectively). Differences in height SDS at diagnosis and last follow-up were not statistically notable in any of the three conditions.
Treatment modalities
The highest rate of complete resections was achieved in XG (86%), compared with 36% of complete resections in RC and 41% in CP (P ϭ 0.004). The surgical approach was transsphenoidal in 14% of CP, in 40% of RC, and in 64% of XG patients. The transcranial approached was chosen in 83% of CP, in 40% of RC, and in 36% of XG patients. An endoscopic approach was used in 4% of CP and 10% of RC patients.
Irradiation was performed in 44 of 117 CP (38%) and in two of 14 RC (14%); irradiation was not deemed necessary for XG. Two patients with recurrent RC were irradiated after multiple relapses following repeated incomplete resections. One RC relapsed 6 months after initial transsphenoidal incomplete resection, followed by a second relapse 6 months after second incomplete resection. External irradiation (54.0 Gy) performed 3 months after the second relapse resulted in complete remission. The other patient with relapsed RC was surgically treated four times for relapses during the first 3 yr after initial diagnosis. External irradiation (50.4 Gy) was performed 3 yr after initial diagnosis. A cystic recurrence was successfully treated by intracystic instillation of bleomycin.
Six of seven RC patients, none of whom received irradiation after incomplete resection, remained in complete remission without progression and presented in good general condition, assessed by FMH (FMH percentile at last evaluation: median, 49th percentile; range, 16 -90th). The seventh RC patient was lost to follow-up.
Postsurgical endocrine deficiencies were most pronounced in XG (93%) and CP (95%) patients when compared with RC (79%). Deficiencies of all four axes (hypocortisolism, hypothyroidism, diabetes insipidus, GH) were found in 57% of XG, in 52% of CP, and in none of RC patients (P Ͻ 0.001). A total 86% of XG and 81% of CP patients presented with persistent postsurgical diabetes insipidus. The rate of visual impairment as diagnosed before surgery in 15% of XG patients and 55% of CP patients did not significantly change after surgery (17% in XG and 56% in CP, respectively).
Postsurgical outcome and follow-up
Whereas 5-yr OS was high in all patient groups (CP, 0.97 Ϯ 0.02; XG, 1.00 Ϯ 0.0; RC, 1.00 Ϯ 0.0), differences in terms of EFS were detectable (P ϭ 0.002). Events in terms of relapse or progression of residual tumor occurred only in CP (5-yr EFS, 0.52 Ϯ 0.05) and RC (5-yr EFS, 0.85 Ϯ 0.10). No relapses or progressions occurred in XG (5-yr EFS, 1.00 Ϯ 0.0).
Progressions after incomplete resection were confirmed by reference assessment in patients with CP (5-yr EFS, 0.40 Ϯ 0.06) and in patients with RC (5-year EFS, 0.76 Ϯ 0.15) (P Ͻ 0.001) (Fig. 4) . Relapses after complete resection occurred only in CP (5-yr EFS, 0.72 Ϯ 0.07). After incomplete resection, 24% of irradiated CP patients and 60% of nonirradiated CP patients developed progression of residual CP (P Ͻ 0.001). Postsurgical lesions of posterior hypothalamic structures (second degree) were detectable only in CP (44%). Differences in terms of functional capacity as measured by FMH did not reach statistical differences between analyzed groups of pa- tients with CP, RC, and XG ( Table 1 ). The self-assessment on QoL (PEDQOL) was not statistically notably different between RC and CP patients (data not shown). PEDQOL was not performed by RC patients.
Center size and neurosurgical experience
Patient characteristics, neurosurgical treatment strategies and outcome varied among the 50 participating neurosurgical centers (three large centers, 24 medium-size centers, and 23 small centers) for CP ( Table 2) . CP patients treated in small centers presented with a higher presurgical rate of hypothalamic involvement (second degree) compared with medium (P ϭ 0.001) and large centers (P ϭ 0.003). In large centers, the intention to treat was less radical in comparison with medium (P Ͻ 0.001) and small centers (P ϭ 0.001). The rates of complete resections and hypothalamic surgical lesions were lower for CP patients treated in large centers when compared with medium (P ϭ 0.037; P ϭ 0.032) and small centers (P ϭ 0.018; P Ͻ 0.001), respectively. After a 36-month follow-up, the degree of obesity was lower and the self-assessed QoL (PEDQOL domain social function) was higher in patients treated in large centers compared with small centers (Ta- Large centers recruited more than five patients during the 6-yr recruitment period of KRANIOPHARYNGEOM 2000; medium-sized centers recruited two to five patients, and small-sized centers recruited one patient per 6 yr recruitment. Presurgical hypothalamic involvement (HI) and postoperative surgical hypothalamic lesions (HL) were reference-assessed based on a grading system previously published by Müller et al. (7) . 0°, No HI/HL; 1°, first degree; 2°, second degree; dgx, diagnosis; NS, nonsignificant.
ble 2). XG and RC patients were treated almost exclusively in large centers with nonimpaired outcome in terms of obesity and QoL (Table 2) .
Discussion
Rathke's cyst RCs are benign lesions of the pituitary region typically lying within the pars intermedia. They are the most common incidentally discovered sellar lesions and are found in 13-33% of routine autopsies (14) . They present as intrasellar cysts with 60% of them showing suprasellar extension (15, 16) . Their size ranges from a few millimeters to 10 -20 mm; cases with a cyst size up to 45-50 mm have also been described (15) .
In our series of patients with childhood RC treated surgically (100%) and by irradiation (14%), we have shown a 5-yr progression-free survival rate of 85% but considerable endocrine morbidity. According to the literature, symptomatic RCs are rare and the manifestations are the result of compression to adjacent structures (17) . In our series, the median duration of symptoms was 24 months, ranging from 1-84 months; this is in accord with previously published data, in which the mean duration of symptoms/signs was 9 -24 months (17) (18) (19) (20) . Growth retardation was the most common clinical feature at presentation (57%). Previous series reported headache as the most frequent (55-81%) clinical manifestation at presentation (17, 19 -25) . Major visual field defects were identified in 7% of our RC patients at the time of diagnosis. In previous studies, the frequency ranges from 38 -49% (17-20, 23, 24, 26) , with the size of the cyst correlating with the presence of visual deterioration (23). These differences in clinical features at presentation might be explained by low tumor volumes and missing hypothalamic involvement in our pediatric RC cohort. At presentation, the reported rates of pituitary hormone deficits show wide variation (17-81%), the rate also depending on the method of assessment (18 -26) . Hormonal deficiencies at presentation were not assessed in our pediatric RC series. Due to our multicenter study design and the frequent necessity for emergency surgery, the available endocrine data are incomplete and biased by different methods. A further limitation of our study, besides small cohort size for XR and RC, is that our assessment for postoperative endocrine deficiencies is based only on the necessity of hormonal substitution.
Based on the literature, cyst evacuation combined or not with biopsy/removal of the cyst wall is the statistically optimal management strategy for RC symptomatic cases (26 -29) , resulting in improvement of headaches and visual disturbances (26, 28) . Similarly to CPs (30), recovery of anterior pituitary hormone deficits after surgery is not common (18 -20, 23, 26) . At last assessment of our RC cohort, ACTH, GH, and TSH deficiency were found in 36, 64, and 42% of the patients, respectively. The poor endocrine prognosis is probably related to pituitary damage attributed to chronic pressure by the cyst or a result of surgery (19, 23, 25, 31) .
Relapse in RC results from re-accumulation of the cyst fluid, which has been usually detected within 5-6 yr after surgery; notably, recurrences up to 24 yr postoperatively have been reported (18, 19, 21, 22, 24, 26) . In our series, during a mean follow-up period of 7 yr, relapses were found in 14% of the patients. Previously reported data, most of which are based on relatively short observation periods in mainly adult cohorts, show recurrence rates ranging widely from 0 -42% (17, 18, 21, 23, 25, 26) . Although not a widely accepted treatment strategy (26) , aggressive resection of cyst wall may prevent relapse (19) but may also be associated with a higher rate of postoperative complications (26) . Two of our 14 RC patients had multiple relapses requiring four surgical interventions. Although such aggressive behavior has been previously reported (20, 24) , it is overall very rare.
In this series of patients with RC followed up for a mean period of 7.2 yr, we have shown that despite the benign pathological appearance of these lesions, there is a considerable relapse rate necessitating long-term monitoring. Based on the observational design of our study and the small cohort size, reliable conclusions on the comparative efficacy of different treatment options such as surgery, irradiation, and treatment timing are difficult. However, what we can confirm is that irradiation and/or intracystic treatment have been efficient second-line treatment options in our cohort.
Sellar XG
In 1999, Paulus et al. (4) reported in a series of 110 cases, which were originally diagnosed as CP, 37 patients with distinct histological features, which appeared to be xanthogranulomatous components. A comparison of those 37 patients with CP showed that they differed from classical CP in age, site, and prognosis (4). Unlike CP with age peaks around 5 and 50 yr, XG of the sella occurs predominantly in adolescents and young adults. The disease is rare, and most publications on XG of the sellar region are case reports on adult patients (32) (33) (34) (35) (36) (37) (38) . In 14 of 131 (11%) patients with sellar masses registered between 2001 and 2006 at the German Childhood Cancer Registry, the diagnosis XG of the sellar region was confirmed by neuropathological review. Based on the high degree of recruiting completeness, the yearly incidence of childhood XG can be estimated as 0.05 per million population.
About 10% of all pediatric sellar masses are XG, similar to a series of adult patients (32) .
Our analyses of a pediatric cohort confirm the findings of Paulus et al. (4) , showing that XG are characterized by smaller tumor size, longer preoperative history, lower frequency of calcifications and visual impairment, better resectability, and more favorable outcome compared with CP. In contrast to the Paulus series, XG in our pediatric cohort presented with high rates of hypothalamic involvement (46%) and intra-and extrasellar localization (92%) and a comparable rate of endocrine deficiencies when compared with CP. These differences might indicate a specific biological characteristic of childhood XG. However, the outcome in XG was favorable, showing no relapse or progression after surgical treatment. Furthermore, hypothalamic obesity at initial presentation or as sequelae was not a clinical feature in XG, despite the considerable high rate of anterior hypothalamic involvement.
Comparison of RC and XG with CP
Despite high survival rates (87-95%) in recent series (9), QoL is frequently and radically impaired in long-term CP survivors due to sequelae caused by the anatomical proximity of CP to the optic nerve, pituitary gland, and hypothalamus (7), including untreatable obesity, behavioral disturbances, and visual impairment (39) .
In our cohort, CP was characterized by high rates of suprasellar localization, involvement and postsurgical lesions of posterior hypothalamic structures and calcifications, larger tumor volume, hydrocephalus at presentation, and hypothalamic obesity at presentation and during follow-up compared with RC and XG. Compared with childhood CP, RC diagnosed during childhood and adolescence was characterized by smaller intrasellar masses without hypothalamic involvement/surgical lesions, leading to severe pituitary deficiencies without hypothalamic sequelae, such as obesity. A radical surgical approach with the intention to preserve integrity of hypothalamic structures seems appropriate for childhood RC. However, a high rate of relapses/progressions, which in our RC cohort exclusively occurred during the first 2 yr after primary surgery, indicates that regular monitoring is warranted, especially during short-term follow-up, to secure immediate and efficient second-line treatment in case of relapses, i.e. irradiation and/or intracystic treatment options.
Childhood XG in our cohort was characterized by a high rate of suprasellar extension and hypothalamic involvement limited to anterior hypothalamic structures (first degree). Nevertheless, radical surgical resection with respect to the hypothalamic and optical structures seems to be the treatment of choice. Clinical features are dominated by pituitary deficiencies, but symptoms due to hypothalamic damage, such as severe obesity, are rare. Accordingly, survival rates and QoL prognosis were best in XG when compared with CP and RC.
Based on our observations, CP is clearly characterized by more frequent and extensive involvement of posterior hypothalamic structures compared with XG and RC cases. This biological feature, complicated by frequent postsurgical lesions mainly of the posterior hypothalamic structures, exerts challenging adverse effects on the treatment and sequelae in CP. Answers to these challenges may come from the few studies analyzing the outcome of patients with craniopharyngioma in relation to the neurosurgeons' experience. Sanford (40) reported a marked difference in outcome according to the neurosurgeon's experience with the condition. In our study, CP treatment in large centers was less radical, and the rates of complete resection and hypothalamic surgical lesions were lower than those of medium-and small-sized centers. Adverse late effects in terms of obesity occurred more frequently in CP patients treated in neurosurgical centers with lower neurosurgical patient load and more radical treatment strategies compared with centers with a larger neurosurgical patient load and therefore have more experience with neurosurgical techniques required in treating CP. Accordingly, treatment of patients with CP/sellar masses should be confined to experienced multidisciplinary centers.
